Semaglutide vs Tirzepatide Weight Loss: Which GLP-1 Is Right for You?
⚡ Key Takeaways Semaglutide (Ozempic, Wegovy) is a GLP-1 receptor agonist; tirzepatide (Mounjaro, Zepbound) is a dual GLP-1 and GIP receptor agonist. In the head-to-head SURMOUNT-5 trial, tirzepatide produced greater average weight loss (~20%) than semaglutide (~14%) at 72 weeks. Both are highly effective, both are weekly injections, and both share similar gastrointestinal side effects. The “better” option depends on your health […]